JEERI NEOTECH INTERNATIONAL
JN-International Medical Corporation is a U.S. based biopharmaceutical corporation which since 1998 has been focused on developing vaccines and diagnostics for infectious disease for developing countries. This private corporation (formerly known as Jeeri Neotech International, Inc) was founded in 1998 by Dr. Jeeri R. Reddy with the help of Dr. Kelly F. Lechtenberg in a small rural town, Oakland, Nebraska. From there it grew and expanded until in the year 2000 the corporation moved to Omaha, Nebraska. JN-International Medical Corporation (JNIMC) has overseas business offices and clinical trial centers located in Abidjan, Ivory Coast in Africa and in Kuala Lumpur, Malaysia, with vaccine cold chain facilities in Burkina Faso and Singaporel.
JEERI NEOTECH INTERNATIONAL
Social Links:
Industry:
Biotechnology Health Care Health Diagnostics
Founded:
1988-01-01
Address:
Omaha, Nebraska, United States
Country:
United States
Website Url:
http://www.jn-vaccines.org
Total Employee:
1+
Status:
Active
Contact:
402-884-3477
Email Addresses:
[email protected]
Total Funding:
12.41 M USD
Technology used in webpage:
SSL By Default DigiCert SSL AddThis Encryption Everywhere Shockwave Flash Embed Yahoo DNS Yahoo Yahoo! Business Email
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Founder
More informations about "Jeeri Neotech International"
Quick takes: WHO vaccine advisers recommend sticking with JN.1 …
1 hour ago The World Health Organization (WHO) today announced that its Technical Advisory Group on COVID-19 Vaccine Composition recently met to review the latest SARS-CoV-2 …See details»
JN-International Medical Corporation - Pharmaceutical …
JN-International Medical Corporation (JNI), a US-based private biopharmaceutical corporation, develops infectious disease vaccines and diagnostics. Founded in 1997 by Dr Jeeri R Reddy in rural Oakland, Nebraska, JNI expanded and …See details»
Statement on the antigen composition of COVID-19 …
Apr 26, 2024 The objective of an update to COVID-19 vaccine antigen composition is to enhance vaccine-induced immune responses to circulating SARS-CoV-2 variants. As the virus is expected to continue to evolve from …See details»
15042024 JN.1 URE clean - World Health Organization (WHO)
Apr 15, 2024 Updated Risk Evaluation of JN.1, 15 April 2024 JN.1 is a descendent lineage of BA.2.86, with the earliest sample collected on 25 August 2023 (1). As of 6 April 2024, there …See details»
02022024_JN.1_URE_clean - World Health Organization
Feb 9, 2024 JN.1 is a descendent lineage of BA.2.86, with the earliest sample collected on 25 August 2023 (1). As of 5 February 2024, there were 79107 JN.1 sequences submitted to …See details»
18122023 JN.1 IRE clean - World Health Organization (WHO)
Due to differential vaccine coverage and circulation of SARS-CoV-2 variants around the world, population immunity remains heterogenous globally and therefore, the immune escape …See details»
ETF recommends updating COVID-19 vaccines to …
Apr 30, 2024 JN.1 differs from the XBB family targeted by previous updated vaccines and has now surpassed the XBB variants to become the most widely circulating variant worldwide. In making its recommendation, the ETF …See details»
Novavax Prepared to Deliver Protein-based Non-mRNA JN.1 …
Apr 26, 2024 Today the World Health Organization’s (WHO) Technical Advisory Group on COVID-19 Vaccine Composition recommended the use of a monovalent JN.1 lineage COVID …See details»
COVID-19: WHO designates JN.1 ‘variant of interest’ …
Dec 20, 2023 The UN World Health Organization (WHO) has said it is continuously monitoring the global spread of JN.1, a COVID-19 variant of interest, adding that current vaccines continue to offer protection against severe …See details»
COVID-19: WHO designates JN.1 ‘variant of interest’ …
Dec 20, 2023 The UN World Health Organization (WHO) has said it is continuously monitoring the global spread of JN.1, a COVID-19 variant of interest, adding that current vaccines continue to offer protection ...See details»
FDA committee recommends updated COVID vaccines for fall
Update 6/13/24: The FDA has updated its guidance to manufacturers, asking them to use the KP.2 strain from the JN.1 lineage "if feasible" to better match circulating strains.It said it does …See details»
JN.1 as a new variant of COVID-19 – editorial - PMC
The JN.1. variation is the subject of ongoing research into its features and possible consequences. Variant JN.1 poses significant challenges to global COVID-19 efforts due to its …See details»
Will COVID Vaccines Continue to Work Against JN.1 and Other …
Jan 31, 2024 The groups that have been at risk for severe disease throughout the pandemic (e.g., elderly persons, the unvaccinated, those with multiple medical conditions, those who are …See details»
What to Know About JN.1, the Latest SARS-CoV-2 “Variant of …
JN.1’s spike protein has just 1 more mutation than BA.2.86’s spike. That mutation, called L455S, enhances the virus’ ability to bind to the angiotensin-converting enzyme 2 (ACE2) receptor, …See details»
Covid-19: WHO adds JN.1 as new variant of interest - The BMJ
Dec 21, 2023 The World Health Organization has added a new covid-19 strain, JN.1, to its list of “variants of interest,” its second highest level of monitoring. Itself an offshoot of the omicron …See details»
Novavax Prepared to Deliver Protein-based Non-mRNA JN.1 …
Apr 26, 2024 Today the World Health Organization’s (WHO) Technical Advisory Group on COVID-19 Vaccine Composition recommended the use of a monovalent JN.1 lineage COVID …See details»
Arrival of JN.1 COVID-19 vaccines and latest vaccination …
Nov 12, 2024 In light of earlier recommendations by the World Health Organization (WHO) and the Scientific Committee on Vaccine Preventable Diseases and the Scientific Committee on …See details»
Package leaflet: Information for the user Comirnaty JN.1 30
Comirnaty JN.1 is given as an injection of 0.3 mL into a muscle of your upper arm. You will receive 1 injection, regardless whether you have received a COVID-19 vaccine before. If you …See details»
RACGP - Why the emergence of JN.1 is significant - NewsGP
Jan 29, 2024 Since it was detected in August 2023, the JN.1 variant of COVID has spread widely. It has become dominant in Australia and around the world, driving the biggest COVID …See details»